Rank: #25 (Last year: #24) ¥693.2 Billion ($4.62 Billion)
Prior Fiscal: ¥659.6 Billion
Percentage Change: +5.0%
R&D Expenditure: ¥157.1B (total)
Best FY24 Quarter: Q4 ¥206.1B
Latest Quarter: Q4 ¥206.1B
No. of Employees: 72,593 (total)
Global Headquarters: Minato City, Tokyo, Japan

This past February, Fujifilm began a partnership with EndoSim, a company that specializes in evidence-based endoscopic simulation. The partnership expanded access to EndoGel, a training model that simulates human tissue so endoscopists can practice submucosal dissection (ESD) and peroral endoscopic myotomy (POEM) procedures. EndoGel launched in Europe in April 2024, and Fujifilm transferred exclusive U.S. distribution of EndoGel to EndoSim.

The rationale for this collaboration was the training gap for ESD and POEM procedures in the U.S. The minimally invasive endoscopic surgical procedure, Fujifilm declared, is more widely used in Asian healthcare markets. Further, the gap arose from lack of practice material to train on complex procedure methods and led Fujifilm to bring EndoGel to the U.S. in 2022.

EndoGel simulates the texture of human tissue involved in ESD and POEM procedures. Endoscopy professionals can use it to practice marking and injecting, perform circumferential incisions, and perform submucosal dissection, myotomy, and clipping.

“As part of Fujifilm’s commitment to endoscopy innovation, we are dedicated to bridging the educational divide in advanced procedures in the United States,” Tai Fujita, general manager of endoscopy, Fujifilm Healthcare Americas Corporation, said in a press release announcing the partnership. “By partnering with EndoSim to expand distributorship of EndoGel, together we are not just filling a training gap; we are setting new standards for education in endoscopic procedures that ultimately lead to better patient care.”

“We believe that EndoGel will be a valuable addition to our products and services in interventional endoscopy simulation,” added EndoSim founder and CEO Kai Matthes, M.D., Ph.D. “The ease of use of EndoGel will provide seamless access to practice novel, third space endoscopic procedures in the clinical setting when access to a hands-on lab is not available. EndoGel can be used in the endoscopy unit without the requirement to have dedicated endoscopic equipment for procedural training.”

Endoscopy is a major part of Fujifilm’s Medical Systems business, which also includes other medical imaging and software products, among others. The business pocketed ¥693.2 billion ($4.62 billion) in its most recent fiscal year (ended March 31, 2025). This represented 5% growth.

The company highlighted higher endoscope sales in Japan, the U.S., Europe, and China as the main drivers of growth in the Medical Systems business. There was also strong performance in medical IT, including Picture Archiving and Communication System (PACS) and in-vitro diagnostics products.

In March 2024, the company earned FDA clearance for CAD EYE, an artificial intelligence (AI) detection system for endoscopic imaging. It consists of a compatible expansion unit (the Fujifilm EX-1) and endoscopy support software (EW10-EC02). The technology allows real-time detection of colonic mucosal lesions like polyps and adenomas during colonoscopies.

When it spots a suspicious polyp, CAD EYE notifies the physician with a “Detection Box” that appears, a “Visual Assist Circle” that illuminates the area, and sounds an alert. The visual cues are then overlaid onto existing clinical images as needed. CAD EYE works with both White Light Imaging and Fujifilm’s Linked Color Imaging, which differentiates the red color spectrum to enhance visualization of mucosa.

The company’s first-of its-kind OPIE transducer for on-pump intracardiac echocardiography (OPIE) for septal myectomy rolled out in April. With OPIE, a thin transducer is passed into the heart during a myectomy to avoid creating a ventricular septal defect while resecting enough myocardium, which can be a pitfall of using transesophageal echocardiography (TEE) before performing septal myectomy. The transducer is compatible with Fujifilm’s Arietta Precision ultrasound system.

Also in April, Brainlab became the exclusive U.S. distributor of Fujifilm’s Arietta Preicison ultrasound for neurosurgery, to be used with Brainlab’s surgical navigation systems. The merged system offers setup for cranial imaging and “plug-and-play” workflows with precalibrated and sterilizable neurosurgery transducers. Neurosurgeons are provided automatic view layouts and can superimpose intraoperative 3D ultrasound scans onto the pre-op dataset for comprehensive overview of the resection cavity.

Using the combined tech, surgeons can visualize misalignment between an intraoperatively acquired 3D ultrasound scan and a preoperative MRI with Brainlab Ultrasound Navigation software. Brainlab’s Elements Ultrasound Snap to MRI software also enables automated rigid fusion between the pre-op MRI image and the intraoperative ultrasound image, allowing surgeons to update the registration and navigate on updated patient anatomy.

June saw the rollout of a new compact, 128-slice computed tomography (CT) system, FCT iStream. The CT captures 60 images a second and uses the company’s SynergyDrive to automate, simplify, and accelerate scanning by assisting with patient positioning, mapping imaging parameters, and scanning and archiving the images. FCT iStream features HiMAR Plus for metal artifact reduction, Intelli IPV to enhance image sharpness, and IntelliODM to reduce radiation dose.

The U.S. debut of the Aperto Lucent 0.4T MRI system came in July. The system boasts a single-pillar design and permanent magnet tech, with a wide, laterally moving table to complement an open architecture. Its RADAR motion compensating pulse sequence tech reduces the need for rescans and minimizes artifacts. CHESS type RF fat saturation complements STIR and Dixon type FatSep sequences for a comprehensive fat suppression capability, and eight channels of active patient shimming offer field uniformity to support fat suppression and image quality.

Aperto Lucent’s spatial resolution and high signal-to-noise ratio (SNR) are promoted by sensitive solenoid technology RF receiver coils and IP-Recon, Fujifilm’s iterative reconstruction algorithm. IPRecon mitigates image noise using a wavelet transform approach, which helps provide high-quality images under demanding resolution requirements.

Fujifilm and Karl Storz began teaming up in August to jointly market Fujifilm’s flexible GI endoscopes with OR integration solutions from Karl Storz. The duo hopes to create a modern GI suite by allowing surgical ORs, routine and interventional hospital suites, and ambulatory surgical centers to experience the benefits of OR integration and flexible endoscopes. Through modular integration, information from these scopes can be streamed, captured, archived, and broadcast along with input from other sources to provide meaningful clinical information for surgeons.

October witnessed release of the Version 10 (v10) suite of software for the company’s Echelon Synergy 1.5T system. It features Synergy Vision, which combines multiple in-bore cameras with StillShot AI to mitigate impact of motion artifacts. StillShot applies AI to correct motion-compromised raw data, referencing real time motion tracking collected during the scan. A new Synergy DLR Clear AI-based algorithm addresses the truncation artifact without extending the scan time, and deep learning enhanced AutoPose provides automatic slice selection combined with expansion to whole bold application for automated table movement.

A week before the end of its fiscal year in March 2025, Fujifilm launched the EN-840T double balloon enteroscopy (DBE) scope, an endoscope that allows access to the whole small intestine for diagnosis and therapeutic intervention. The scope’s 3.2 mm working channel suits many procedures requiring hemostasis and balloon dilation, and allows for blood or mucus aspiration while a therapeutic device is inserted. The scope also has a dedicated forward water jet channel for irrigation and to quickly clear debris on the mucous membranes for clearer bowel wall visualization. A CMOS image sensor in the scope creates vivid, HD images, and adaptive bending and advanced force transmission tech provide better access and scope maneuverability.

The company also began a strategic agreement with Amazon Web Services (AWS) a week before its most recent fiscal year ended. AWS will bolster cloud hosting capabilities for Fujifilm’s North American Synapse enterprise imaging customers.

AWS validated Fujifilm’s Synapse enterprise PACS—specifically Radiology PACS, Cardiology PACS, Digital Pathology PACS, and the Synapse VNA—for cloud readiness. AWS cloud services enable Fujifilm to offer cloud security and the ability to scale to any size Synapse organization, supporting Synapse customers as they transition from legacy data centers to public cloud infrastructure.

¥659.6 Billion ($4.36 Billion)
Prior Fiscal: ¥622 Billion
Percentage Change: -5.4%
R&D Expenditure: ¥157.1B (total)
Best FY23 Quarter: Q4 ¥190.2B
Latest Quarter: Q4 ¥190.2B
No. of Employees: 1,521

In November 2023, Fujifilm announced its Synapse 7x enterprise imaging platform was granted a Risk Management Framework (RMF) and Authority to Operate (ATO) on U.S. Department of Defense Networks. The ATO was awarded for the upgraded platform after almost five years of operating on the company’s earlier Synapse 5 platform.

Synapse 7x unites data and imaging from radiology, mammography, cardiology, 3D, and other enterprise imaging on hardware-independent, cloud-deployable server-side rendering technology. Using Synapse 7x, organizations in the DoD network can access a PACS platform that reaches across the enterprise and is an improvement from radiology-specific PACS platforms.

“The U.S. Government standards for security are extremely high, demonstrating Fujifilm has exceeded the strictest expectations for securing our technology,” said Bill Lacy, senior VP, medical informatics, Fujifilm Healthcare Americas Corporation. “We are proud to have earned the ATO for our Synapse 7x Enterprise Imaging technology, which is poised to improve data access throughout the Military Health System.”

Fujifilm’s Medical Systems business accrued ¥659.6 billion ($4.36 billion) in its FY 2023 (ended March 21, 2024). In terms of yen, this represented 6% growth over the prior fiscal year. In terms of U.S. dollars, it represented a 5.4% loss from the prior year, due to unfavorable currency conversion headwinds. Consolidated operating income was ¥97.4 billion, down 5.2% year-over-year.

The company pointed to steady sales of endoscopes and CT/MRI systems as the main driver of growth in the Medical Systems business. In the endoscopes field, sales of 7000 System products rose significantly in Japan, the U.S., and China. CT/MRI proceeds benefitted from higher sales in South/Central America, the Middle East, and India.

The company obtained FDA clearance for the Echelon Synergy 1.5T MRI system in August 2023. The system uses Synergy DLR, a proprietary deep learning reconstruction (DLR) technology powered by AI to enhance image sharpness and acquire scans more quickly. The MRI’s AutoExam One Touch also offers an automated workflow for brain and knee exams, automatically positioning the patient and beginning the exam after the scan room door is closed. Echelon Synergy’s bore is 70 cm wide with a 63 cm-wide table to accommodate patients up to 550 pounds.

Several new medical systems were unveiled at last November’s Radiological Society of North America (RSNA) meeting:

• • Essentia FS and Essentia SA. Essentia FS is a compact digital radiography floor-mounted system with a 10-inch graphic display at the tube. Essentia SA is a compact straight-arm system designed for a range of standing, sitting, and recumbent radiographic exams.

• • Persona RF Premium+, a multi-use fluoroscopy system for imaging skeletal, digestive, urinary, respiratory, and reproductive systems; and specific organs including the heart, lung, and kidneys.

• • Persona C-HR, a mobile fluoroscopy C-arm solution that touts 30 frames per second pulsed fluoroscopy images at a low dose. Its opening measures 81 cm and it weighs 200 pounds less than other systems in its class.

• • Aperto Lucent Plus MR imaging technology that’s based on a permanent magnet system with a 0.4T static field strength and space-saving gantry design. It has a single-pillar, 320° open view design to simultaneously reduce space requirements and simplify exam access.

The SCALE EYE laser-equipped colonoscope and endoscopy support software received an FDA nod in February 2024. SCALE EYE displays a linear or circular measurement on the endoscopy monitor so endoscopists can estimate colorectal lesion size in vivo without needing visual estimations, consumable tools, or further surgical instruments. Fujifilm claims Scale Eye offers more accurate, objective colon polyp size measurement compared to biopsy forceps methods.

The CAD-Eye AI detection system for endoscopic imaging’s FDA clearance followed in March 2024. Consisting of the EX-1 compatible expansion unit and EW10-ECO2 endoscopy software, CAD-Eye offers real-time detection of colonic mucosal lesions. When a suspicious polyp is spotted, the physician is given visual and auditory alerts. A “detection box” appears, a “visual assist circle” illuminates the area, and an alert is sounded that can be customized to the clinician’s preference. The visual images are overlaid on top of clinical images in the existing workflow.

Rising sales of the company’s Amulet Innovality digital mammography system in South/Central America and the U.S. bolstered the company’s X-ray diagnostics field, along with expansion of the maintenance service business in Japan and Europe. In medical IT, sales increased because of strong performance of the Picture Archiving and Communication System (PACS) Synapse and the 3D image analysis system Synapse Vincent, mainly in major markets like Japan, the U.S., and Europe.

Fujifilm began transferring its business related to electronic medical records (EMR) and medical receipt systems to PHC Holdings in April 2023 after a stock purchase agreement. PHC’s subsidiary Wemex Corp. acquired all shares of the EMR and medical receipt business, and the acquisition was completed in October.

The newly acquired Synapse Pathology debuted at last April’s Healthcare Information and Management Systems Society annual meeting. The open, vendor-agnostic, end-to-end solution uses slide images to create a direction for pathology digitization across labs. Meant for medical facilities handling large volumes of pathology images and data in multiple locations, Synapse Pathology, according to the company, delivers digital images for diagnosis 1.7 hours faster than glass sides. It also facilitates patient case sharing with subspecialists to boost cross-departmental collaboration.

The D-EVO Suite OTCx hit the U.S. market in September 2023. The overhead tube crane system uses the company’s FDR D-EVO III high-resolution, high sensitivity ultra-lightweight, glass-free detectors coupled with Dynamic Visualization, the company’s intelligent image processing. This processing uses feature recognition to automatically optimize visualization adjusting for individual variations in anatomy. It also features a large 10.5 inch technologist-friendly touchscreen display at the tube head, enabling techs to fine-tune exam parameters while remaining at the patient’s side.

Ultrasound Diagnostics revenue was flat due to strong Japanese sales of the DeepInsight series overcoming sluggish sales in China. In-vitro diagnostics revenue also grew because higher sales of the Fuji DRI-CHEM blood biochemical test equipment and slides outweighed lower demand for COVID-19-related reagents.

The Sonosite ST point-of-care ultrasound (POCUS) launched in May 2023. It features a 21-inch all-touchscreen interface, a large 10” by 7.5” image area, automated setting optimization for each exam type, and Auto Steep Needle Profiling (SNP). Optimized exam types for common POCUS-guided procedures are also included, for nerve block administration in regional anesthesia, vascular access in emergency medicine, and joint injections in musculoskeletal care.

Sonosite Voice Assist was released in February 2024. The voice command feature enables control of Sonosite PX and Sonosite LX systems hands-free during sterile or clean procedures, including central venous access, peripheral nerve blocks, among many other intricate procedures. Users can freeze and save images, adjust gain settings, and add color flow all through a voice command.

¥611.1 Billion ($4.61 Billion)
Prior Fiscal: ¥533.8 Billion
Percentage Change: +14.5%
R&D Expenditure: ¥154.1B (total)
Best FY22 Quarter: Q4 ¥176.1B
Latest Quarter: Q4 ¥176.1B
No. of Employees: 73,878 (total)

During the summer of 2020, cancer informatics and digital pathology solution provider Inspirata announced it was partnering with Fujifilm to distribute and service the former’s digital pathology workflow software. Digital pathology is the digitization of pathology slides to conduct software visualization analysis of a specimen rather than using microscopic slides. The arrangement was made for the worldwide marketplace, and came with exclusivity within the U.K., Italy, Spain, Portugal, Belgium, the Netherlands, and Luxembourg.

Inspirata’s scanner-agnostic solution made for a good match for Fujifilm’s technology, bridging a technical gap between pathology, radiology, and oncology. The company’s respective systems Synapse (Fujifilm) and Dynamyx (Inspirata) integrated well together, enabling a seamless solution for customers.

Fast-forward to the close of the 2022 calendar year and it was announced Fujifilm was to acquire the assets of Inspirata’s Dynamyx digital pathology business, moving customers and employees over to the Japanese-based firm. Much of the industry still relies on analog solutions for pathology, so the opportunity for growth for Fujifilm with the buy was significant.

“Since launching our European partnership with Inspirata three years ago, we’ve seen great success implementing our combined technologies in several healthcare organizations, notably in the U.K.,” explained Masa Fukumoto, managing director, FUJIFILM Healthcare Europe and senior vice president, FUJIFILM Medical Systems Europe. “We’ve received feedback from customers anticipating digitizing pathology will be the most transformative thing they do for their practice, and we look forward to continuing our global expansion.”

Approximately a month later, the deal was closed. The creation of a digital pathology division expands Fujifilm’s Synapse Enterprise Imaging offering to enable the digitization and integration of pathology images and data into a healthcare organization’s electronic health record system and to help streamline care delivery for oncology patients and provider teams.

The Synapse Enterprise Imaging system enables healthcare organizations to allow staff to take advantage of real-time, cross-departmental collaboration with views of the entire patient. It features a number of capabilities for different clinical areas under a single umbrella product. In addition to the aforementioned Pathology PACS solution, other offerings include Cardiovascular Select; PACS for Enterprise, Radiology, and Cardiology; Vendor-Neutral Archive; and more.

The addition of the Pathology offering wasn’t the only improvement to the system. In November, Fujifilm announced it had released Synapse 7.2, the newest version of its Synapse 7x enterprise picture archiving and communication system (PACS). This product unites radiology, mammography, cardiology, and enterprise imaging on an all-encompassing, server-side rendering, cloud deployable, diagnostic PACS viewer. Version 7.2 delivers more than 80 new workflow features and advanced toolsets to enhance the efficiency of clinical radiology and cardiology users, as well as IT professionals.

Another addition to the system was the incorporation of Synapse Analytics, a cloud-based data mining extraction engine that enables healthcare organizations to analyze business data to see current and predictive views of their business operations. The secure and customizable software engine provides tracking and insights of trends in procedure volume, patient population analysis, lab operation efficiency, profitability, and diagnostic accuracy. Further, the Analytics product could be applied throughout the Synapse portfolio, bringing analytics capabilities to healthcare providers and administrators across the enterprise.

Synapse also gained credibility from an independent source—the U.S. Department of Defense (DoD)—when it awarded a Pacific Air Force/ Navy (PACAF) contract to the organization for its software product. The contract was given to incorporate the Synapse PACS system into U.S. Naval and Air Force medical treatment facilities’ PACS. According to Fujifilm, it was the DoD’s vendor of choice for this award due to Synapse PACS’s ability to strengthen government healthcare operations through robust integrations with imaging modalities, improved system services, and enhanced image distribution for clinical users across 14 U.S. Naval and Air Force medical treatment facilities. The following criteria established by the U.S. government for PACS vendor selection were met:

• • PACS to effectively integrate with voice recognition/dictation system, provide a solution for critical test result management, and multi-site region-wide peer review for radiologists on their PACS workstations.

• • PACS to seamlessly integrate with the Army and Navy Enterprise Clinical Imaging Archive and the Air Force’s Data Center Image Repositories.

Outside of PACS, the company had several other product announcements. In May, the firm launched Vevo F2, an ultra-high to low frequency (71MHz-1MHz) ultrasound and photoacoustic imaging system for preclinical use. The product features HD image processing technology and introduces a new signal pathway—from transducer to display screen. This enables better image clarity, and when combined with multi-line processing, delivers significantly improved frame rates over earlier generation platforms.

In addition, the company launched the FDR Cross—a hybrid C-arm and portable X-ray for hospitals and ambulatory surgery centers—in the U.S. According to Fujifilm, the dual-function C-arm is the first of its kind to offer portable fluoroscopic and radiographic imaging on one platform, reducing the need to bring in additional imaging equipment for essential image-guided procedures.

Fujifilm also gained FDA 510(k) clearance for the EG-740UT linear endoscopic ultrasound scope (EUS), which is compatible with its ARIETTA 850 ultrasound processor. The EUS scope was designed for diagnostic and therapeutic endoscopic ultrasound procedures in the upper digestive tract.

In November, the firm announced the U.S. launch of the SCENARIA View Focus Edition Computed Tomography system—a scanner with an advanced Cardiac Motion Correction feature, called Cardio StillShot. The system is designed for routine and advanced clinical applications, including coronary computed tomography angiography, interventional CT, extended coverage shuttle scanning for perfusion exams, and dual energy examinations.

The company will lean heavily on these innovations to continue the growth trajectory it enjoyed during its latest fiscal year. The Medical Systems segment of Fujifilm Healthcare accounted for two-thirds of total sales revenue for the unit. It contributed ¥611.1 billion to the company’s coffers, reflecting a rise of over 14%, while the entire Healthcare segment tallied ¥917.9 billion.

¥533.8 Billion ($4.38 Billion)
Prior Fiscal: ¥349 Billion
Percentage Change: +53%
R&D Expenditure: ¥150.5B (total)
Best FY21 Quarter: Q4 ¥154.2B
Latest Quarter: Q4 ¥154.2B
No. of Employees: 75,474 (total)

FUJIFILM Corporation began its 2021 fiscal period with a big splash; it announced FUJIFILM Healthcare Corporation joined the Fujifilm Group. Essentially, the unit represents the addition of Hitachi’s diagnostic imaging-related business, which was officially transferred to FUJIFILM as of March 31, 2021.

The deal—first announced in December 2019—was valued at approximately ¥179 billion ($1.63 billion). The transaction brought Hitachi’s comprehensive suite of imaging solutions (primarily CT, MRI, X-ray, and ultrasound systems) to FUJIFILM’s Medical Systems business, which is home to the organization’s medtech offerings.

According to FUJIFILM, the purchase would transition the company into a one-stop total imaging and diagnostics solutions provider with solutions that include CT, MRI diagnostics imaging, medical IT, in-vitro diagnostics, and endoscopy as primary offerings. Further, it enables synergies to be realized between Medical Systems and other healthcare-related segments, such as those providing pharmaceuticals and regenerative medicine. In addition, combining the firm’s image processing capabilities utilized in picture archiving communication systems (PACS) with AI technologies, Fujifilm would be able to develop and provide new value-added solutions. Ultimately, the company would seek to deliver offerings such as “AI-supported diagnosis” and “AI-supported maintenance.”

Then in October 2021, it was announced the former Hitachi group (FUJIFILM Healthcare Americas Corporation) would merge with FUJIFILM Medical Systems U.S.A. Inc. to become FUJIFILM Healthcare Americas Corporation.

“We have built a new foundation leveraging the strengths of each organization to demonstrate the clinical value and relevance of our combined portfolio,” proclaimed Henry Izawa, president and CEO of FUJIFILM Healthcare Americas Corporation. “Integrating two of Fujifilm’s key healthcare businesses enhances our ability to become an even more comprehensive healthcare partner for our customers.”

The combination strengthens a FUJIFILM business that was already excelling in its specific care areas. The Medical Systems unit is the largest (by far) in terms of revenue within the Healthcare segment. In its 2021 fiscal, the business as a whole rose 38.4% as compared to the previous period. In real-world financial terms, that equated to ¥801.7 billion in revenue. Medical Systems went from its FY20 total of ¥340 billion to ¥533.8 billion in FY21.

Elsewhere within the healthcare segment, BIO CDMO (biologics contract development and manufacturing organization) also saw a fantastic rise, going from ¥113.2 billion to ¥150.3 billion. The LS Solutions unit (Life Sciences), on the other hand, remained virtually even with the prior period. It showed minimal growth—¥117.2 billion in FY2020 to ¥117.6 billion in FY2021.

In addition to optimizing its Medical Systems business with the combination of two separate units, FUJIFILM also focused on future growth through organic means. That is, it progressed on a bevy of products during the 12-month timeframe, launching some and announcing positive regulatory review news for others.

The G-EYE 700 Series colonoscope was launched in April 2021. G-EYE is a technology developed by Smart Medical to assist with visualization, stabilization, and control during routine examinations. Through a strategic distribution partnership, Fujifilm is able to provide the company’s G-EYE endoscope line to European customers.

The organization also launched the Persona RF PREMIUM in the U.S, a radiography and fluoroscopy system designed for hospitals and medical centers of all sizes. It provides real-time imaging for skeletal, digestive, urinary, respiratory, and reproductive systems, as well as specific organs including the heart, lung, and kidneys.

June saw the launch of the company’s Systems Integration platform, designed specifically to enhance image and data integration in endoscopy suites. Through specially designed hardware and software configurations, this scalable solution enables the multi-video and image routing and display capabilities that GI physicians need while performing advanced procedures. The platform delivers a variety of differentiated benefits for endoscopy suites, including quad-channel recording, teleconferencing/broadcasting, interoperability and image recall, and educational and training capabilities.

The U.S. FDA granted 510(k) clearance of an image enhancement technology—the Oxygen Saturation Endoscopic Imaging System—developed to improve visualization during gastrointestinal, colorectal, and advanced endoscopy and surgical procedures. The solution enables real-time visualization of hemoglobin oxygen saturation levels in tissue using laparoscopic and/or endoscopic imaging, helping surgeons identify potentially ischemic tissue and better positioning them to prevent tissue necrosis. An upgrade to this technology—the ELUXEO 7000X System—was launched at the Society of American Gastrointestinal and Endoscopic Surgeons conference in Las Vegas at the end of August.

Perhaps in response to the challenges of demonstrating technologies in-person during the pandemic, the organization launched the Fujifilm Virtual Hospital in the summer of 2021. The virtual hospital presents visitors with an interactive environment where they can view and learn about Fujifilm’s portfolio of healthcare solutions, and discover how the company’s diagnostic, treatment, and research technologies advance the entire continuum of patient care. Upon the initial opening of the Fujifilm Virtual Hospital, a helpful pop-up with instructions aids visitors in taking a self-guided tour of the “facility.” Visitors can also request a virtual or in-person demonstration to learn more about specific offerings.

The firm also launched what it stated was the first FDA-cleared dual-channel endoscope—the El-740D/S—for use in both upper and lower gastrointestinal applications. The device provides high imaging quality and features dual channel diameters of 3.7 mm and 3.2 mm, enabling use of a range of endotherapy devices.

In mid-November, the industry saw the debut of the Persona CS mobile fluoroscopy system, the company’s compact mobile C-arm imaging solution designed for rapid and seamless positioning in operating room environments. The system was designed to provide enhanced live image guidance during a wide range of surgeries, including orthopedic, complicated surgical, pain management (anesthetics), and emergency procedures.

During the 2021 Radiological Society of North America (RSNA) conference in Chicago, the Velocity MRI System was launched. The unit was designed to streamline workflow and enhance the patient experience with its unique open gantry, integrated radiofrequency coils, and reconstruction technologies. According to FUJIFILM, the anatomy-conformable Synergy Flex coil is the first of its kind for an open, vertical field MRI scanner, promoting fast abdominal and orthopedic imaging.

A couple weeks before the start of the new year, a technology was launched to improve the endoscopic submucosal dissection (ESD) technique. Inserted through the instrument channel of an endoscope, TRACMOTION’s 360° rotatable jaws enable easy grasping and re-grasping of large lesions, which enhances a clinician’s visualization, simplifies the lesion extraction process, and offers the potential to reduce ESD procedure times.

FUJIFILM Sonosite is a provider of point-of-care ultrasound (POCUS) solutions and in February 2022, launched the Sonosite LX system. This technology offers the company’s largest clinical image and a monitor that extends, rotates, and tilts to enable enhanced, real-time provider collaboration. The clinical display features touchscreen controls to enable an optimized heads-up workflow, allowing clinicians to keep their eyes on the image while making adjustments. In addition, designed to be used with the Sonosite LX and Sonosite PX, the company also launched a T8-3 transesophageal transducer and Cardiac Resuscitation exam type to assist clinicians in using transesophageal ultrasound at the point of care.

Beyond its activity with product development, FUJIFILM also teamed with an assortment of partners to collaborate on several projects.

In one such instance, FUJIFILM Medical Systems U.S.A. joined forces with Helio Health in an effort to advance blood-based screening methods for early-stage liver cancer. Helio Health is an AI-driven healthcare company developing early cancer detection tests. Through the relationship, Helio Health’s DNA methylation and biomarker-based blood test technology, recognized as the HelioLiver Test, would leverage Fujifilm’s 510(k)-cleared µTASWako i30 Immunological test system for liver cancer biomarkers.

In a different effort, FUJIFILM Medical Systems U.S.A. and ScreenPoint Medical paired up to offer providers with an AI solution designed for early breast cancer detection. Through this arrangement, FUJIFILM’s ASPIRE Cristalle mammography system with digital breast tomosynthesis would also offer ScreenPoint’s FDA-cleared Transpara powered by Fusion AI for 2D and 3D mammography in the U.S. ScreenPoint’s AI solution, coupled with the ASPIRE Cristalle mammography system, displays breast screening findings at a doctor’s reading workstation or PACS system.

In still another combination, FUJIFILM VisualSonics and PIUR IMAGING, a European provider of tomographic ultrasound imaging, partnered to bring UHF, 3D ultrasound imaging technology to clinicians and researchers. The technological advancement would support clinical research in the evaluation of anomalies in several applications, including dermatology, neurology, vascular, and MSK.